1. Home
  2. PLRZ vs SNGX Comparison

PLRZ vs SNGX Comparison

Compare PLRZ & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLRZ
  • SNGX
  • Stock Information
  • Founded
  • PLRZ 2005
  • SNGX 1987
  • Country
  • PLRZ Israel
  • SNGX United States
  • Employees
  • PLRZ N/A
  • SNGX N/A
  • Industry
  • PLRZ
  • SNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PLRZ
  • SNGX Health Care
  • Exchange
  • PLRZ NYSE
  • SNGX Nasdaq
  • Market Cap
  • PLRZ 3.7M
  • SNGX 4.3M
  • IPO Year
  • PLRZ 2024
  • SNGX 1987
  • Fundamental
  • Price
  • PLRZ $1.09
  • SNGX $2.74
  • Analyst Decision
  • PLRZ
  • SNGX Strong Buy
  • Analyst Count
  • PLRZ 0
  • SNGX 1
  • Target Price
  • PLRZ N/A
  • SNGX $6.00
  • AVG Volume (30 Days)
  • PLRZ 16.3M
  • SNGX 19.3M
  • Earning Date
  • PLRZ 02-15-2025
  • SNGX 08-12-2025
  • Dividend Yield
  • PLRZ N/A
  • SNGX N/A
  • EPS Growth
  • PLRZ N/A
  • SNGX N/A
  • EPS
  • PLRZ N/A
  • SNGX N/A
  • Revenue
  • PLRZ N/A
  • SNGX $2,342.00
  • Revenue This Year
  • PLRZ N/A
  • SNGX N/A
  • Revenue Next Year
  • PLRZ N/A
  • SNGX N/A
  • P/E Ratio
  • PLRZ N/A
  • SNGX N/A
  • Revenue Growth
  • PLRZ N/A
  • SNGX N/A
  • 52 Week Low
  • PLRZ $0.55
  • SNGX $1.09
  • 52 Week High
  • PLRZ $1,200.00
  • SNGX $5.40
  • Technical
  • Relative Strength Index (RSI)
  • PLRZ N/A
  • SNGX 77.06
  • Support Level
  • PLRZ N/A
  • SNGX $1.18
  • Resistance Level
  • PLRZ N/A
  • SNGX $5.38
  • Average True Range (ATR)
  • PLRZ 0.00
  • SNGX 0.38
  • MACD
  • PLRZ 0.00
  • SNGX 0.16
  • Stochastic Oscillator
  • PLRZ 0.00
  • SNGX 37.14

About PLRZ POLYRIZON LTD

Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: